Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Litfulo

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM

Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

- PMLiVE

Researchers develop microneedle patch to reverse hair loss caused by alopecia areata

The autoimmune skin condition currently affects more than six million people in the US

- PMLiVE

Pfizer’s sickle cell disease therapy Oxbryta recommended by NICE for NHS use

About 4,000 people in England with the genetic blood disorder are expected to benefit from the decision

- PMLiVE

Bristol Myers Squibb and Repertoire enter autoimmune disease partnership worth over $1.8bn

It is estimated that up to 50 million people in the US have an autoimmune disease

- PMLiVE

Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer

It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year

- PMLiVE

Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approval

More than 38,000 people worldwide are currently affected by the rare genetic bleeding disorder

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

NICE recommends Menarini’s Nexpovio combination to treat multiple myeloma

More than 4,500 new patients are diagnosed with this form of blood cancer every year in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links